Influenza (quadrivalent, split virion) vaccine is under clinical development by Changchun Institute of Biological Products and currently in Phase I for Influenza A Virus, H1N1 Subtype Infections. According to GlobalData, Phase I drugs for Influenza A Virus, H1N1 Subtype Infections have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Influenza (quadrivalent, split virion) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Influenza (quadrivalent, split virion) vaccine overview
Vaccine is under development for the prevention of influenza virus B infection, influenza A virus H1N1 and H3N2 subtype infections. It is a quadrivalent inactivated influenza split vaccine and is administered through intramuscular route.
Changchun Institute of Biological Products overview
Changchun Institute of Biological Products, a subsidiary of China National Pharmaceutical Group Corp, engaged in development, manufacturing and supply of recombinant protein therapeutic products, diagnostic reagents and viral vaccines. The company is headquartered in Changchun, Jilin, China.
For a complete picture of Influenza (quadrivalent, split virion) vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
